reports
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
DAI DAIMLER AG
KORI KORIAN SA
GLE SOCIETE GENERALE S.A. CLASS A
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
CCL CARNIVAL PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
WBD WEBUILD S.P.A.
WLN WORLDLINE SA
RACE FERRARI NV
SAB BANCO DE SABADELL SA
STLA STELLANTIS N.V.
OVH OVH GROUPE
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
DAI DAIMLER AG
KORI KORIAN SA
GLE SOCIETE GENERALE S.A. CLASS A
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
CCL CARNIVAL PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
WBD WEBUILD S.P.A.
WLN WORLDLINE SA
RACE FERRARI NV
SAB BANCO DE SABADELL SA
STLA STELLANTIS N.V.
OVH OVH GROUPE
Press Release: Riliprubart earns orphan drug designation in the US for...
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipientsRiliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administ...
Communiqué de presse : Le riliprubart est désigné comme médicament orp...
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet actif induit par les anticorps chez les receveurs de transplantation du reinLe riliprubart a également été désigné comme médicament orphelin pour l’utilisation expérimen...
- Research Department
IBERIAN DAILY 24 JUNE (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: GRIFOLS. Stock markets welcome the possible truce between Iran and Israel, as opposed to crude oil The strikes on Iran nuclear sites had a limited impact on European stock markets, which ended with drops below -0.5%. US indices saw greater gains and crude oil fell sharply after Iran’s failed missile attack to the US base in Qatar, followed by a 12-hour truce between Iran and Israel announced by D. Trump. In the STOXX 600, Utilities and Technology were the best performers whereas B...
- Research Department
INFORME DIARIO 24 JUNIO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: GRIFOLS. Las bolsas festejan la posible tregua Irán-Israel, el crudo no El bombardeo estadounidense a las plantas de desarrollo nuclear iraníes tuvo un impacto limitado entre las bolsas europeas, que cerraron con caídas inferiores al medio punto porcentual. Los índices estadounidenses acentuaron las ganancias y el petróleo registró fuertes caídas tras el ataque fallido de Irán con misiles a bases americanas en Qatar, seguida de una tregua de 12 hor...
- Research Department
IBERIAN DAILY 23 JUNE (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: AEDAS, IAG, INDRA, NEINOR, OHLA. US attacks Iran The risk of a military intervention by the US in Iran weighed on the market last week, and the 2-week deadline decided by D. Trump calmed stock markets. However, the movement of the military arsenal continued in the Middle East area, and in the end the US launched a weekend air attack on 3 Iranian nuclear targets. In the STOXX 600, Real Estate and Energy saw the biggest gains last week vs. Pharma and Retail that ended with the bigge...
- Research Department
INFORME DIARIO 23 JUNIO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AEDAS, IAG, INDRA, NEINOR, OHLA. EUROPA: SCHNEIDER ELECTRIC. EE.UU. ataca Irán El riesgo de una intervención militar de EE.UU. en Irán sobrevoló sobre el mercado durante la semana pasada y el plazo de dos semanas que se había dado D. Trump alivió a las bolsas. Sin embargo, el movimiento de arsenal militar seguía llegando a la zona de O. Medio y finalmente EE.UU. ha lanzado durante el fin de semana un ataque aéreo sobre 3 objetivos nucleares. Irán h...
Press Release: Sarclisa recommended for EU approval by the CHMP to tre...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd aloneIf approved, it would represent the fourth indication in the EU and second in the front-line setting globally Paris, June 23, 2025. The European Medicines Agency’s Commi...
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE ...
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Recommandation fondée sur l’étude de phase 3 GMMG-HD7, qui a montré que l’ajout de Sarclisa au traitement d’induction VRd améliorait significativement le taux de négativité de la MRD (maladie résiduelle minimale) et prolongeait la SSP (survie ...
Press Release: Dupixent approved in the US as the only targeted medici...
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BPBP is a chronic, debilitating, and relapsing rare skin disease affecting approximately 27,000 adults in the US whose disease is uncontrolled by systemic corticosteroidsDupixent is now approved in the US t...
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le s...
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission durable de la maladie et une réduction des démangeaisons ainsi que de l’utilisation de corticoïdes oraux par rapport au placebo chez les adultes atteints de PBLa PB est une maladie chronique rare, invalidante et récurrente de...
- Christian Arnold
- Tobias Fahrenholz
LHN HOLCIM AG
FME FRESENIUS MEDICAL CARE AG
CLN CLARIANT AG
BVI BUREAU VERITAS SA
ROG ROCHE HOLDING LTD
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
ARYN ARYZTA AG
NESN NESTLE S.A.
OERL OC OERLIKON CORPORATION AG
REE RED ELECTRICA CORP. SA
GEBN GEBERIT AG
BAS BASF SE
SAN SANOFI
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
LPP LPP S.A.
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
SIK SIKA AG
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
GSK GSK PLC
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
NOVO B NOVO NORDISK A/S
SFZN SIEGFRIED HOLDING AG
- Christian Arnold
- Tobias Fahrenholz
LHN HOLCIM AG
FME FRESENIUS MEDICAL CARE AG
CLN CLARIANT AG
BVI BUREAU VERITAS SA
ROG ROCHE HOLDING LTD
DKSH DKSH HOLDING AG
NOVN NOVARTIS AG
GIVN GIVAUDAN SA
LONN LONZA GROUP AG
ARYN ARYZTA AG
NESN NESTLE S.A.
OERL OC OERLIKON CORPORATION AG
REE RED ELECTRICA CORP. SA
GEBN GEBERIT AG
BAS BASF SE
SAN SANOFI
IMPN IMPLENIA AG
SUN SULZER AG
RIEN RIETER HOLDING AG
DOKA DORMAKABA HOLDING AG
LPP LPP S.A.
YPSN YPSOMED HOLDING AG
BCHN BURCKHARDT COMPRESSION HOLDING AG
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
VACN VAT GROUP AG
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
SIK SIKA AG
SRAIL STADLER RAIL AG
STMN STRAUMANN HOLDING AG
GSK GSK PLC
ACLN ACCELLERON INDUSTRIES LTD
DSFIR KONINKLIJKE DSM N.V.
SGSN SGS SA
NOVO B NOVO NORDISK A/S
SFZN SIEGFRIED HOLDING AG
- Team Pharma
- Research Department
IBERIAN DAILY 18 JUNE (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: CIE AUTOMOTIVE, ELECTRICITY SECTOR, IAG, TALGO. Ups and downs on the market European stock markets were back in the red, while the conflict between Israel and Iran entered its fifth day, and before the Fed’s decision today. In the STOXX 600, only Energy and Real Estate ended in green numbers, whereas Banks and Travel & Leisure once again posted the biggest losses. On the macro side, in Germany the ZEW index improved more than expected in June thanks to the fiscal measures announce...
- Team Pharma
Press release: Sanofi successfully prices €1.5 billion bond issue
Press release: Sanofi successfully prices €1.5 billion bond issue Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an annual rate of 2.625%.€750 million fixed-rate notes, due June 2032, bearing interest at an annual rate of 3.000%. The notes are being issued off the company's Euro Medium Term Note Programme. Sanofi intends to use the net proceeds of the offering for general corporat...
Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts ob...
Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires Sanofi place 1,5 milliard d’euros d’emprunts obligataires Paris, 17 juin 2025 - Sanofi annonce avoir placé avec succès une émission obligataire en 2 tranches (les « obligations ») pour un montant de 1,5 milliard d’euros : 750 millions d’euros d’obligations à taux fixe, échéance juin 2029, portant intérêt au taux annuel de 2,625%. 750 millions d’euros d’obligations à taux fixe, échéance juin 2032, portant intérêt au taux annuel de 3,000%. Les obligations ont été émises dans le cadre du programme...
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (o...
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.